

13<sup>th</sup> January, 2025

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Intimation as per Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

**Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31<sup>st</sup> December, 2024**

**Board Meeting on Tuesday, 28<sup>th</sup> January, 2025**

Dear Sir / Madam,

Pursuant to Regulation 29 of the Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, 28<sup>th</sup> January, 2025, *inter alia* to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter ended 31<sup>st</sup> December, 2024.

In this regard, we also write to inform you that the 'Trading Window' for dealing in the securities of the Company, which has been closed from Wednesday, 1<sup>st</sup> January, 2025 will remain closed till Thursday, 30<sup>th</sup> January, 2025 (both days inclusive).

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

**Piramal Pharma Limited**

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India  
T: +91 22 3802 3000 / 4000; Email: [shareholders.ppl@piramal.com](mailto:shareholders.ppl@piramal.com)

[piramalpharma.com](http://piramalpharma.com)